Oral Carmofur in Advanced Gastrointestinal Cancer
| Autor: | Seppo Pyrhönen, Reijo Salmi, Pentti Gröhn, Erkki Heinonen, Hillevi Länsimies, E. Kumpulainen, Asta Lantto, Soile Numminen |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Adolescent Colorectal cancer Administration Oral Antineoplastic Agents Gastroenterology Drug Administration Schedule chemistry.chemical_compound Stomach Neoplasms Pancreatic cancer Internal medicine medicine Humans Gastrointestinal cancer Adverse effect Aged Urinary bladder Rectal Neoplasms business.industry Cancer Middle Aged medicine.disease Pancreatic Neoplasms Carmofur medicine.anatomical_structure Oncology chemistry Fluorouracil Colonic Neoplasms Female business medicine.drug |
| Zdroj: | American Journal of Clinical Oncology. 13:477-479 |
| ISSN: | 0277-3732 |
| DOI: | 10.1097/00000421-199012000-00005 |
| Popis: | One hundred and twenty-four patients with a diagnosis of metastatic gastrointestinal cancer and no prior therapy were included in this clinical study of carmofur monotherapy, 300-500 mg/m2 daily for 6 weeks. For the 115 evaluable patients, the response rates were 19.4% in gastric cancer, 27.2% in cancer of mobile colon, and 12.5% in rectal cancer. No objective responses were seen in 38 patients with pancreatic cancer, although the disease of 13 of these patients has remained stable over a considerably long period of follow-up. The toxicity profile was interesting; the main adverse effects were urinary bladder symptoms and flush. Hematologic toxicity was minimal. The treatment proved to be safe and could be used for outpatients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|